Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer

Journal of the American Geriatrics Society

Volumn 60, Issue 9, 2012, Pages 1761-1767

  Becker, Taryn ^a,b   Lipscombe, Lorraine ^a,b,c   Narod, Steven ^a,b   Simmons, Christine ^a,d   Anderson, Geoffrey M ^a,b,c   Rochon, Paula A ^a,b,c  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

aromatase inhibitors; bone and bones; breast cancer; fracture

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ANASTROZOLE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; TAMOXIFEN;

AGING; BONE DENSITY; BONE REMODELING; BONE TURNOVER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; EARLY CANCER; FRACTURE; HUMAN; MEDICAL DECISION MAKING; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BONE DENSITY; BREAST NEOPLASMS; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84866384302     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2012.04107.x     Document Type: Review

References (34)

1. Canadian Cancer Society Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2011. Toronto, ON: Canadian Cancer Society, 2011.
2. SEER cancer statistics review, 1975-2009 (Vintage 2009 populations). National Cancer Institute, Bethesda, MD, Based on November 2011 SEER Data Submission [on-line]. Available at http://seer.cancer.gov/csr/1975-2009-pops09/ Accessed June 28, 2012.
3. Crivellari D, Sun Z, Coates AS, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: The BIG 1-98 trial. J Clin Oncol 2008; 26: 1972-1979.
4. Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK expert group. Cancer Treat Rev 2008; 34 (Suppl 1): S3-S18.
5. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
6. Thurlimann B, Keshaviah A, Coates AS, et al. Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-2757.
7. Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis. J Natl Cancer Inst 2011; 103: 1299-1309.
8. Saad F, Adachi JD, Brown JP, et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008; 26: 5465-5476.
9. Bjarnason NH, Hitz M, Jorgensen NR, et al. Adverse bone effects during pharmacological breast cancer therapy. Acta Oncol 2008; 47: 747-754.
10. Haentjens P, Magaziner J, Colon-Emeric CS, et al. Meta-analysis: Excess mortality after hip fracture among older women and men. Ann Intern Med 2010; 152: 380-390.
11. Ioannidis G, Papaioannou A, Hopman WM, et al. Relation between fractures and mortality: Results from the Canadian Multicentre Osteoporosis Study. Can Med Assoc J 2009; 181: 265-271.
12. Tosteson AN, Gottlieb DJ, Radley DC, et al. Excess mortality following hip fracture: The role of underlying health status. Osteoporos Int 2007; 18: 1463-1472.
13. Brown JP, Josse RG, Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002; 167 (10 Suppl): S1-S34.
14. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262-1271.
15. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
16. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455-462.
17. Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 study. J Clin Oncol 2007; 25: 2664-2670.
18. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian tamoxifen anastrozole trial. J Clin Oncol 2005; 23: 5138-5147.
19. Aihara T, Takatsuka Y, Ohsumi S, et al. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. Breast Cancer Res Treat 2010; 121: 379-387.
20. Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 2008; 26: 1965-1971.
21. Hadji P, Ziller M, Kieback DG, et al. The effect of exemestane or tamoxifen on markers of bone turnover: Results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. Breast 2009; 18: 159-164.
22. Hadji P, Ziller M, Kieback DG, et al. Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: Results of a German, 12-month, prospective, randomised substudy. Ann Oncol 2009; 20: 1203-1209.
23. Gonnelli S, Cadirni A, Caffarelli C, et al. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 2007; 40: 205-210.
24. Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006; 21: 1215-1223.
25. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol 2007; 8: 119-127.
26. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17. J Clin Oncol 2006; 24: 3629-3635.
27. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230. J Clin Oncol 2008; 26: 1051-1057.
28. Rabaglio M, Sun Z, Price KN, et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009; 20: 1489-1498.
29. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
30. Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary. Can Med Assoc J 2010; 182: 1864-1873.
31. Neuner JM, Yen TW, Sparapani RA, et al. Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients. Osteoporos Int 2011; 22: 2847-2855.
32. Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: Practical guidance for prevention and treatment. Ann Oncol 2011; 22: 2546-2555.
33. Papaioannou A, Kennedy CC, Dolovich L, et al. Patient adherence to osteoporosis medications: Problems, consequences and management strategies. Drugs Aging 2007; 24: 37-55.
34. van Helden S, van Geel AC, Geusens PP, et al. Bone and fall-related fracture risks in women and men with a recent clinical fracture. J Bone Joint Surg Am 2008; 90: 241-248.